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Renal cell carcinoma in children and young adults: analysis of clinicopathological,
immunohistochemical and molecular characteristics with an emphasis on the spectrum of
Xp11.2 translocation-associated and unusual clear cell subtypes
Aims: Recent studies suggest that paediatric renal cell
carcinoma (RCC) may represent a distinct group of
tumours; however, its biological behaviour and classi-
fication remain poorly understood. The aim was to
analyse 13 RCCs from patients £23 years of age
to determine their clinicopathological, immunohisto-
chemical and molecular characteristics.
Methods and results: The histological spectrum inclu-
ded: Xp11.2 translocation-associated (6 ⁄ 13 patients,
46%), clear cell (5 ⁄ 13 patients, 38%), papillary (1 ⁄ 13
patients) and unclassified (1 ⁄ 13 patients) types. The
Xp11.2 translocation-associated RCCs had a wide
morphological spectrum, with high nuclear grade cells
with abundant cytoplasm ranging from clear to gran-
ular and architecture ranging from solid to papillary.
These tumours lacked cytokeratin expression and were
confirmed by nuclear reactivity for TFE3 protein. Most
of these translocation-associated tumours presented at
high stage and had an unfavourable outcome. Three
clear cell RCCs had unusual features that have not
been previously characterized, including solid and
cystic architecture, cells with abundant eosinophilic
cytoplasm yet low nuclear grade and focal cytoplasmic
inclusions, resembling oncocytoma. Deletion of sub-
telomeric 3p25 was observed in two of these RCCs.
Conclusions: Xp11.2 translocation-associated RCC
represents a predominant and aggressive subtype in
the paediatric age group. Increased awareness of
this subtype is important due to its heterogeneous
morphology.
Keywords: renal cell carcinoma in children and young adults, TFE3, Xp11.2 translocation-associated renal cell
carcinoma
Abbreviations: AMACR, a-methylacyl CoA racemase; BMT, bone marrow transplant; CA, carbonic anhydrase;
CK, cytokeratin; EMA, epithelial membrane antigen; FISH, fluorescence in situ hybridization; FN, Fuhrman nuclear;
IL, interleukin; PCKD, polycystic kidney diseases; RCC, renal cell carcinoma; vHL, von Hippel Lindau; WHO,
World Health Organization
Introduction
Renal cell carcinoma (RCC) accounts for 90% of renal
tumours in adults, with a peak occurrence in the sixth
decade, and is the sixth most common cause of
cancer-related death in the USA. In contrast, RCC in
childhood is relatively rare, accounting for approxi-
mately 6% of malignant paediatric tumours and <4%
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of paediatric renal tumours.1–3 Genetic, immuno-
histochemical and histological data have led to the
reclassification of RCC in the last decade.4 Recent
evidence has indicated that paediatric RCC is a distinct
entity with important clinical and prognostic associ-
ations. Paediatric RCC lacks the male:female gender
predilection as well as associations with environmen-
tal factors that are often present in adult RCC.1,5,6
Whereas local lymph node metastases are a poor
prognostic indicator in adult RCC, some studies have
suggested a good outcome for paediatric RCC despite
lymph node metastases.7,8
In addition, paediatric RCC is histopathologically
and genetically distinctive. Unusual subtypes of RCC
have been described, predominantly among children
and young adults. A relatively novel paediatric RCC
that is defined by its distinctive translocation has
been coined the Xp11.2 translocation carcinoma.
These tumours most commonly harbour either t(X;
17)(p11.2;q25), which leads to a fusion of the
transcription factor gene TFE3 with the ASPL gene;
t(X;1)(p11.2;p34), which leads to the fusion of the
TFE3 gene with the PSF gene; or t(X;1)(p11.2;q21),
which leads to a fusion of the TFE3 gene with the
PRCC gene.4,9 Morphologically, these tumours have
nested to pseudopapillary patterns, distinctive volumi-
nous eosinophilic to clear cytoplasm and numer-
ous psammoma bodies.10,11 A recently developed
antibody for the immunohistochemical identification
of TFE3 protein, which is thought to be constitutively
overexpressed in these carcinomas, has been shown
to be a highly sensitive and specific marker in these
carcinomas.12
Despite the evidence that paediatric RCC is distinct
from adult RCC, there have been relatively few
published series of paediatric RCC.1,2,5,7,8,13–15 Some
of these studies were also reported before the introduc-
tion of the 2004 World Health Organization (WHO)
classification, when Xp11.2 translocation-associated
RCC was proposed as a distinct molecular subtype.1,14
In this study we retrospectively analysed a series of 13
RCCs occurring in children and young adults to
delineate further the clinical, gross, morphological,
immunohistochemical and molecular features of RCC
in this age group.
Materials and methods
case selection
The files of the Department of Pathology at University
of Michigan were searched for all radical or partial
nephrectomies with a diagnosis of RCC in patients
£23 years of age between January 1986 and June
2006. An age cut-off of 23 years was chosen because it
is similar to that used in other series.2 None of these
cases has been previously reported. All haematoxylin
and eosin-stained sections were reviewed (R.B.S., L.P.K.
and A.W.). All RCCs were assigned a Fuhrman nuclear
(FN) grade16 and were classified using criteria proposed
in the 2004 WHO classification.4 Tumours classified as
Xp11.2 translocation-associated carcinomas had pre-
viously described morphological features9–11,17 and
were immunohistochemically positive for TFE3 protein
expression.12 All cases were staged according to the
2002 American Joint Committee on Cancer TNM
staging system.18 Multiple additional pathological
parameters including tumour size, architecture, cyto-
plasmic characteristics, presence of foamy macrophages,
necrosis, focality and laterality were recorded for the
study cases. In addition, demographic data (age, sex)
and follow-up information (presence of recurrence,
metastasis or death) were obtained from available
clinical charts.
immunohistochemistry
Representative paraffin-embedded tissue blocks were
selected in all cases for immunohistochemistry, which
was performed using an avidin–biotin–peroxidase com-
plex technique. In one case (case 8), representative
blocks were not available for immunohistochemistry.
When available, immunohistochemistry previously
performed during the initial diagnosis of each case
was reviewed.
An extended immunohistochemical panel including
pan-cytokeratin (CK) cocktail [AE1 ⁄ 3 (Chemicon Inter-
national, San Diego, CA, USA), 1:800; Cam5.2 (BD
Biosciences, San Jose, CA, USA), 1:20, 30 min], CAM
5.2 (BD Biosciences, 1:1, 30 min), epithelial membrane
antigen (EMA; Dako, Carpinteria, CA, USA; 1:25,
30 min), CK7 (Dako; 1:125, 30 min), CD10 (Vector
Laboratories, Burlingame CA, USA; 1:10, 30 min), RCC
(Novocastra, Newcastle, UK; 1:100, 30 min), WT1 (Cell
Marque, Rocklin, CA, USA; 1:50, 30 min), HMB45
(Dako; 1:25, 30 min), a-methylacyl CoA racemase
(AMACR; P504S) (Zeta Corporation, Tucson, AZ,
USA; 1:20, 30 min) and TFE3 (Santa Cruz, Santa Cruz,
CA, USA; 1:80, 45 min) was performed. Carbonic
anhydrase IX (CA IX; Novus Biologicals, Littleton, CO,
USA; 1:200, 30 min) immunohistochemistry, a marker
that has previously been described as relatively specific
for clear cell carcinoma,19–21 was performed on selected
cases with unusual morphology that were initially
considered unclassifiable. Three authors (A.W., L.P.K.
and R.B.S.) interpreted the immunohistochemistry
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results, which were scored as positive when >10% of
tumour cells demonstrated strong reactivity with the
antibody. For TFE immunohistochemistry, moderate to
strong nuclear reactivity in tumour cells was considered
to be a positive reaction.
molecular / cytogenetic analysis
Fresh tissue on three tumours was sent for conven-
tional cytogenetic karyotype analysis. One sample was
insufficient for analysis and another was determined to
have a normal karyotype, leaving one tumour with
cytogenetic data included in this study.
Fluorescence in situ hybridization (FISH) analysis to
detect deletion of 3p was performed on three RCCs with
unusual morphology that were initially considered
unclassifiable. The FISH procedure and analysis have
been previously described in detail.22,23 FISH was
performed with centromeric a-satellite DNA probes for
CEP3 (Spectrum Orange) and for the subtelomeric
probe for 3p25 (3pTel25, Spectrum Green). All of the
probes were obtained from Vysis (Downers Grove, IL,
USA) and were diluted with tDenHyb 2 (CEP3-3pTel25)
(Insitus, Albuquerque, NM, USA) in a ratio of 1:100.
The resulting slides were examined by one of the
study authors using a Zeiss Axioplan 2 microscope
(Zeiss, Göttingen, Germany) with the following filters
from Chroma (Chroma, Brattleboro, VT, USA): SP-100
4¢-6-diamidino-2-phenylindole, fluorescein isothiocya-
nate MF-101 for Spectrum Green (subtelomeric
3pTel25) and Gold 31003 for Spectrum Orange
(CEP3). The images were acquired with a charge
coupled device camera and analysed with METASYS-
TEM ISIS Software (MetaSystem, Belmont, MA, USA).
Five sequential focus stacks with 0.4-mm intervals
were acquired and then integrated into a single image
in order to reduce thickness-related artefacts.
The patients diagnosed with von Hippel Lindau
(vHL) syndrome were determined as heterozygous or
homozygous for vHL mutations through direct DNA




Overall, 13 cases of RCC were diagnosed in patients
£23 years old from 1986 to 2006 at our institution,
accounting for <1% of all RCCs diagnosed at our
institution during this time period. In this cohort, nine
patients were male and four female and their ages
ranged from 9 to 23 years (mean 17 years, median
17 years). The most common clinical presentations
were haematuria (n = 4); family history of vHL syn-
drome or symptoms associated with vHL syndrome,
such as liver or pancreatic cysts or hearing loss (n = 2);
abdominal pain (n = 2); or incidentally found renal
tumour on imaging studies (n = 2). One patient had a
history of hepatoblastoma and was post chemotherapy,
and another had tuberous sclerosis and polycystic
kidney disease. Five patients underwent partial
nephrectomy and eight underwent radical nephrec-
tomy. The clinical features of the patients are summa-
rized in Table 1.
clinicopathological, immunohistochemical
and molecular features of rcc subtypes
Histologically, 13 RCCs were divided into five distinct
subgroups: Xp11.2 translocation-associated RCC (6 ⁄ 13
cases, 46%); clear cell RCC (5 ⁄ 13 cases, 38%), vHL
syndrome-associated (n = 2) and sporadic (n = 3);
papillary RCC (1 ⁄ 13 cases); and RCC, unclassified
(1 ⁄ 13 cases).
x p 1 1 . 2 translocation-associated rcc
Six cases (46%) were classified as Xp11.2 trans-
location-associated RCCs. The ages of these patients
were significantly lower (median age 13 years). Four
were unifocal tumours; two consisted of two separate
tumour nodules. Tumour sizes ranged from 35 to
110 mm. Grossly, tumours were well defined, with
yellow to tan-brown variegated cut surfaces, and had a
cortical or subcapsular location, similar to clear cell
RCC (Figure 1A). One tumour had white-tan, ill-
defined borders and arose primarily within the central
portion of the renal parenchyma, possibly within a
calyx, and projected into the renal pelvis. The majority
of these tumours were extensively necrotic.
Morphologically, these tumours were predominantly
composed of cells with voluminous cytoplasm that
ranged from clear to eosinophilic. In most of the
tumours, cell borders in some areas were prominent
and bulging, giving rise to the previously coined ‘soap
bubble’ morphology.9–11,17 Nuclear features within
some tumours varied, from small, uniform nuclei to
larger nuclei with prominent nucleoli. However, the
highest FN grade in all tumours was 3. Architecturally,
the tumours were heterogeneous, ranging from solid
sheets, pseudoalveolae, trabeculae, pseudopapillae and
true papillae. Four tumours (cases 1, 2, 3 and 4) had
predominantly eosinophilic to clear cells in nests with a
delicate intervening vascular network, mimicking clear
cell RCC, and areas where the central cells within the
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nests became discohesive, giving rise to a pseudoalve-
olar growth pattern. These four tumours also had a
minor architectural pattern in which the cells were
arranged around true fibrovascular cores, mimicking
papillary RCC (Figure 1B,C,E). Of the remaining two
tumours, one (case 5) was composed entirely of clear
cells and was initially classified as a clear cell RCC; this
tumour was reclassified 3 years after initial presenta-
tion when recurrent tumour with an entirely papillary
architecture was biopsied, and TFE3 immunohisto-
chemistry was performed. The sixth tumour (case 6)
was composed entirely of eosinophilic cells arranged
in papillae, resembling papillary type 2 carcinoma
(Figure 1D), but was classified correctly at initial
resection due to strong TFE3 protein overexpression.
Two tumours had prominent, scattered psammoma
bodies, and no tumours had xanthoma cells.
All of these tumours showed strong nuclear immuno-
reativity for TFE3 protein (Figure 1F), which has been
shown to correlate with TFE3 gene fusion.12 In
addition, despite some very focal positivity for CAM5.2
in a subset of tumours, all of the tumours were
predominantly negative for cytokeratins. All tumours
were also positive for CD10, RCC and AMACR. Details
of the immunohistochemical results are summarized
in Table 2.
Conventional karyotyping analysis was available in
one case (case 3) and found a complex karyotype
involving a translocation between Xp11.2 and 17q21:
55,X,t(X;17)(p11.2;q21),+der(1;12)(q10;q10),+2,i(2)-
(q10),der(3)t(3;17)(q29;q12), +4,+8,+13,+14,+15,
+17,der(17)t(X;17)(p11.2;q21),+20. It is possible that
the TFE3 fusion partner corresponds either to the CLTC
gene on 17q23, which has been recently reported24 or
to some as yet undescribed gene.
clear cell rcc
Five cases (38%) were classified as clear cell RCC; two
arose in patients with vHL syndrome, whereas the
remaining cases were sporadic. Clear cell carcinomas
were more likely to arise in slightly older patients
(median age 20 years). vHL-associated clear cell car-
cinomas were more likely than sporadic clear cell
carcinoma to be multifocal. However, none were
bilateral.
Three of the clear cell RCCs (two vHL-associated and
one sporadic) had typical morphology, characterized by
tumour cells with clear cytoplasm arranged in cords
and trabeculae with a delicate intervening vascular
stroma. These carcinomas also had prominent cystic
change, although none were classified as a multilocular
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Figure 1. Xp11.2 translocation-associated renal cell carcinomas (RCCs) were predominantly well defined, cortical tumours with yellow to
tan-brown variegated cut surfaces (A). These tumours predominantly had heterogeneous morphology; in areas of some tumours, the cells
had abundant, clear cytoplasm with bulging cell borders, mimicking clear cell RCC (B). In other areas, these tumours formed well-defined
papillae, mimicking papillary RCC (C). In fact, one tumour was completely papillary with prominent psammoma bodies and was morphologically
indistinguishable from type 2 papillary RCC (D). Other areas of these tumours had eosinophilic cells arranged in nests in which the central
cells became discohesive, giving rise to a pseudoalveolar pattern (E). All of these tumours showed strong nuclear reactivity by TFE
immunohistochemistry (F).
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Two patients (cases 10 and 11) had clear cell RCCs
with an unusual morphology that initially caused
difficulty in classification. Since one patient had a
tumour with identical morphology in the contralat-
eral kidney 3 years after initial presentation, three
tumours from these two patients were available for
study. These carcinomas had large prominent cystic
spaces that were lined by eosinophilic cells, which in
some areas demonstrated hobnailing, focally mimick-
ing cystic nephroma at low power (Figure 2A). In
solid areas of these tumours, cells with abundant
eosinophilic cytoplasm yet round regular nuclei with-
out visible nucleoli were arranged in nests and
tubules, focally mimicking oncocytoma. Scattered cells
had prominent eosinophilic cytoplasmic inclusions
(Figure 2B). These cases were positive for CD10,
EMA and RCC and were negative for CK cocktail,
CK7 and CAM5.2. All three tumours were strongly
and diffusely positive for CA IX. (Figure 2C). Two of
the three tumours demonstrated loss of one copy of
subtelomeric 3p (Figure 2D). Given these results and
the overall morphology of these tumours, they were
classified as clear cell RCC.
papillary rcc
One 22-year-old patient presented with papillary RCC.
The tumour had characteristic type 2 morphology,
with cells with high FN grade, nuclear stratification,
and abundant voluminous eosinophilic cytoplasm. The
tumour was positive for cytokeratins, CD10 and
AMACR and negative for TFE3.
rcc, unclassif ied
One patient was a 13-year-old girl with tuberous
sclerosis and polycystic kidney disease who had a RCC
arising within a background of angiomyolipoma. The
RCC had a heterogeneous morphology; different areas
resembled clear cell, papillary, or chromophobe RCC
morphology. The areas of carcinoma were focally
immunoreactive for CK cocktail and CAM5.2, strongly
reactive for CD10 and RCC and were immunonegative
for TFE3, whereas the angiomyolipoma component
was strongly reactive for smooth muscle actin and
HMB-45.
clinical stage and outcome
Stage at presentation
The stage at presentation is summarized in Table 1. Of
note, nearly all (four of six) of the Xp11.2 transloca-
tion-associated RCCs presented at higher stage. The
clear cell RCCs and papillary RCC presented at low
stage, whereas the unclassified RCC arising in the
patient with tuberous sclerosis presented at higher
stage.
Outcome
The median follow-up time was 4 years (mean follow-
up time 5.6 years, range 1.7–14.2 years). Of the total
of 13 patients, eight are currently free of primary
disease without any evidence of recurrence after initial
resection. These eight patients include two of the six
Xp11.2 translocation-associated RCCs, the five clear
cell RCCs and the papillary RCC. One patient with a
clear cell RCC with unusual morphology (cells with
eosinophilic cytoplasm and low-grade nuclei) had a
pT1N0M0 tumour with identical morphology and
immunohistochemical profile in the contralateral kid-
ney 3 years after initial resection. This patient is
currently disease free after a partial nephrectomy of
the contralateral tumour.
Of the five remaining patients, one patient with an
Xp11.2 translocation-associated RCC has had recur-
rent tumour in the surgical bed and retroperitoneal
lymph nodes 3 years after initial resection, but is
currently disease free following resection.
Table 2. Immunohistochemistry staining results for all Xp11.2 translocation associated renal cell carcinomas
Case # CK Cocktail Cam 5.2 CK7 EMA CD10 RCC WT1 HMB45 AMACR TFE3
1 ) Focal + ) ) +++ ++ ) ) +++ +++
2 ) ) ) ) +++ +++ ) ) + +++
3 ) ) ) ) +++ + ) ) + +
4 ) Focal + ) ) +++ + ) ) +++ +
5 ) ) ) ) +++ + ) ) ++ +
6 ) ) ) ) +++ + ) ) +++ +
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The three patients who died of disease all had Xp11.2
translocation-associated RCC. Of these patients, one
(case 4) presented with pT1N0M0 disease and was
thought to be disease free following resection, but had
widespread metastatic recurrences 8 years after pre-
sentation. The second patient (case 1) had T1N1M0
disease, also thought to be completely resected, but had
widespread metastatic recurrences 2 years after pre-
sentation. Despite numerous attempts at adjuvant
therapy, including cisplatinin-based chemotherapy,
interleukin (IL)-2 therapy, autologous bone marrow
transplant and Sunitinib, both patients died of progres-
sive tumour burden 9 and 3 years after initial presen-
tation, respectively. The third patient (case 3) had
distant metastases at presentation, was enrolled in an
experimental protocol, but died 2 years after presenta-
tion. The sites for distant metastases were lung, liver,
brain, paratrachea and cervical and periadrenal lymph
nodes.
Finally, the patient with tuberous sclerosis and
polycystic kidney disease with unclassified RCC arising
in a background of angiomyolipoma died of complica-
tions due to end-stage renal disease.
Discussion
RCC in children is a rare disease.3 In our series of 13
cases, RCC in this age group accounted for <1% of all
RCCs diagnosed over a 20-year span. Speculation
remains whether paediatric RCC represents a truly
different entity from its adult counterpart.1,5–8 Our
results suggest that RCCs in this age group share many
A B
C D
Figure 2. Three clear cell renal cell carcinomas (RCCs) have unusual morphological features, including large cystic spaces lined by eosinophilic
cells which are focally hobnailed, superficially mimicking cystic nephroma (A), and cells with eosinophilic cytoplasm yet low nuclear grade with
occasional prominent cytoplasmic inclusions (arrowheads), focally resembling oncocytoma (B). These RCCs were strongly positive for carbonic
anhydrase IX (C), and two tumours show retention of two copies of centromeric 3p (Spectrum Orange) along with loss of one copy of
subtelomeric 3p25 (Spectrum Green) (D).
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similarities to those in adults, yet possess some distinct
clinicopathological characteristics. Contrary to other
paediatric RCC series, we did find a male predominance
(male: female ratio 2:1), similar to that described in
adult RCC.1–3
Although several previous series of paediatric RCC do
not mention any unusual or underlying syndromes,7,14
other series2,13 report approximately 20–30% of
patients with underlying predisposing conditions or
syndromes, such as a history of chemotherapy, neuro-
blastoma ⁄ teratoma, renal failure or tuberous sclerosis.
In our series one of the interesting features was the
association of two clear cell RCCs with vHL syndrome.
Although the reported age of presentation of vHL-
associated RCC is much younger than that reported in
sporadic RCC (mean age of onset 37 versus 61 years),4
in the majority of the previously published paediat-
ric series, vHL-associated RCC has not been repor-
ted.2,5,7,13,14 The ages of the vHL patients in our series
were 20 and 23 years, again confirming that patients
with vHL syndrome present with RCC at much younger
ages. Two other patients had an underlying condition:
one had a history of hepatoblastoma at 1 year old,
underwent resection and cisplatinin and adriamycin
chemotherapy and radiation, and subsequently devel-
oped an Xp11.2-associated RCC 12 years later. This
case supports the reported association of approximately
10–15% of translocation RCC with prior exposure to
cytotoxic chemotherapy.8,17,25–28 Finally, similar to
other paediatric RCC series, we had one patient with
tuberous sclerosis who had a RCC, unclassified type,
arising in the setting of multiple angiomyolipomas.2,13
The reported incidence of the clear cell RCC subtype
in paediatric patients has ranged significantly from low
(6–15%) to high (45–61%), in comparison with that in
adults of 80–90%.2,5,7,13,14 Clear cell RCC accounted
for 38% of our tumours, a much lower incidence than
that reported in adults. Interestingly, three clear cell
RCCs from two patients presented with unusual mor-
phological features that have not been previously
described and have probably been classified as RCC,
unclassified type, in other series.2 These cases had an
unusual morphology that initially caused difficulty in
their classification. These carcinomas were relatively
circumscribed and had large prominent cystic spaces
that were lined by eosinophilic cells, which in some
areas demonstrated hobnailing, focally mimicking
cystic nephroma at low power (Figure 2A). Despite
the fact that eosinophilic cells within clear cell RCCs
generally have higher FN grade,29 in the solid areas
of our tumours the cells had abundant eosinophilic
cytoplasm, yet round regular low-grade nuclei without
visible nucleoli. Cells were arranged in nests and
tubules, focally mimicking oncocytoma (Figure 2B).
Scattered cells had prominent eosinophilic cytoplasmic
inclusions. All tumours were confined to the organ.
Table 3. Summary and comparison of incidence, clinical characteristics, stage, and outcome in recent Xp11.2 translocation
associated renal cell carcinoma series and current series
Author
# of Xp11.2 ⁄
Total cases
of RCC (%)






















(III, IV)* ANED AWD DUD DOD
Bruder2 8 ⁄ 41 (20) 25 13 N ⁄ A N ⁄ A N ⁄ A N ⁄ A N ⁄ A N ⁄ A N ⁄ A
Geller7,15 10 ⁄ 12 (83) 0 0 30 70 2.6 N ⁄ A N ⁄ A N ⁄ A N ⁄ A
Altinok32 6 ⁄ 8 (75) 17 0 67 33 5.8 100** 0 0
Ramphal27 7 ⁄ 13 (54) 14 0 57 43 3.3 86 0 0 14
Selle13 11 ⁄ 49 (22) 9 18 33 67 3.5 91 9 0 0
Geller8 7 ⁄ 11 (64) 14 0 14 86 4 28 14 14 43
Current Study 6 ⁄ 13 (46) 17 0 33 67 2.8 50 0 0 50
N ⁄ A, Not applicable, information not reported; ANED, Alive with no evidence of disease; AWD, Alive with disease; DUD, died
of causes unrelated to disease; DOD, Died of disease.
*Per the 2002 AJCC TNM staging system18; **Information regarding disease status in surviving patients not reported.
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These RCCs were negative for cytokeratins and positive
for CD10, EMA, RCC and CA IX (Figure 2C), a marker
previously described to be relatively specific for clear
cell RCC.19–21 Molecular analysis by FISH demon-
strated loss of one copy of subtelomeric 3p in two of the
three cases, supporting the diagnosis of clear cell RCC
in these cases (Figure 2D).
Xp11.2 translocation-associated RCC has been recen-
tly proposed in the new WHO classification as a distinct
molecular subtype of RCC with a predilection for
paediatric patients, although they are now increasingly
being reported in adults.4,30,31 This subtype is now
thought to represent a significant proportion of RCC in
paediatric patients, with widely divergent incidences
reported in recent series (20–75%).2,8,13,27,32 In our
series, Xp11.2 translocation-associated RCC was the
most common subtype, accounting for 46% of our
tumours. The median age of these patients was only
13 years.
There is controversy relating to the biological
behavior of RCC in children and young adults. Whereas
some series have suggested a good prognosis, others
report that prognosis is dependent on the overall stage
of the tumour and completeness of resection similar to
that seen in adult patients.5,6,13,14,33 In their series of
13 patients, Geller et al. found that four children with
lymph node-positive RCC and without distant meta-
static disease had a very favourable long-term progno-
sis.7 Some early and smaller series have reported a
relatively indolent course in patients with transloca-
tion-associated RCC.11,27 However, in a recent paper by
Geller et al., a literature search of TFE+ RCC series
found that TFE+ RCC are much more likely to present
at higher stage (III ⁄ IV) compared with TFE) RCC.
They also found, however, that 14 of 15 N+M0 TFE3+
RCC patients remain disease free with a median follow-
up of 4.4 years, and therefore argue that local lymph
node metastases in the absence of haematogenous
disease spread does not necessarily portend a worse
prognosis, at least in the short term.8 Complicating
these data is that fact that there have been several case
reports of recurrences occurring as long as 20–
30 years after initial resection of translocation-associ-
ated RCC.28,34,35
In our series the majority (four of six) of Xp11.2
translocation-associated RCCs presented at an advan-
ced stage. The majority also had a poor outcome, with
distant metastases and ⁄ or death, often occurring years
after initial presentation. However, of note, stage at
presentation and completeness of initial resection did
not necessarily correlate with prognosis. For exam-
ple, two patients initially presented with pT1N0M0
tumours and were thought to be disease free following
resection, but developed widespread recurrences 3–
8 years after presentation. One patient with pT1N1M0
disease, thought to be disease free after resection, died
of recurrent disease 3 years after presentation. There
were two patients who presented with relatively high-
stage tumours (pT3N0M0 and pT3N2M0) who are
currently disease and recurrence free. In addition,
although our sample size is small, the absence of
haematogenous metastases did not seem to correlate
with better prognosis. In fact, in our series only one
patient presented with distant metastases; indeed, this
patient died of her disease 2 years after presentation.
However, of the five remaining patients with either
N0M0 or N+M0 disease, three either died from their
disease or had widespread recurrences years after
initial presentation. Indeed, it may be that initial stage
at presentation, completeness of resection, or presence
or absence of haematogenous metastases may be less
important in predicting long-term prognosis in trans-
location-associated RCC than some as yet undefined
underlying marker of tumour biology. Table 3 sum-
marizes the incidence, clinical findings, stage and
outcome of Xp11.2 translocation-associated RCCs
described in our study and in recent paediatric RCC
series.
The Xp11.2 translocation-associated RCCs in our
series were resistant to conventional adjuvant thera-
pies (cisplatinin-based regimens, IL-2 therapy and
autologous bone marrow transplants). However, given
our small sample size, as well as the fact that only a
minority of clear cell RCCs are responsive to IL-2, it is
still unclear whether translocation-associated RCCs
are more resistant to adjuvant therapy than other
histological subtypes. Nevertheless, the strikingly dif-
ferent prognosis between clear cell and papillary RCCs
and Xp11.2 translocation-associated RCCs, along with
the increasing number of experimental trials for
translocation-associated RCCs,8,36,37 underscores the
importance of correctly classifying paediatric RCCs.
From the surgical pathologist’s point of view, increa-
sed awareness of translocation-associated RCC is
critical, as these tumours share significant morpho-
logical overlap with other subtypes, as is evident from
our results. Morphologically, all of our translocation-
associated RCCs focally mimicked other subtypes of
RCC, in particular clear cell and papillary RCC.
Previously described morphological features, including
high-grade tumour cells with voluminous clear to
granular cytoplasm, prominent cell borders and mixed
architectural patterns ranging from a nested and
trabecular growth pattern resembling clear cell RCC
to focally prominent pseudoalveolar and papillary
morphology, were present in four cases. Focally
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prominent psammoma bodies were also seen in two
cases. These features were overall the most reliable
morphological features for this diagnosis.9–11,17 How-
ever, two cases presented with morphology indistin-
guishable from clear cell RCC (case 5) and type 2
papillary RCC (case 6). The only clue to correct
classification in these cases was the patient’s young
age.
All of these tumours either lacked or only weakly
expressed cytokeratins and all demonstrated moderate
to strong nuclear reactivity for TFE3 protein, which
has previously been determined to be a sensitive
and specific marker of TFE3 gene fusion.12 This
marker was negative in all remaining cases. Our
results suggest that any high-grade RCC presenting
with variable features of clear cell and ⁄ or papillary
morphology, prominent nested architecture, psam-
moma bodies, or unusual morphological features
occurring in children and young adults should be
worked up for cytokeratins and TFE3 to rule out this
carcinoma.
In conclusion, our results suggest that RCC in
children and young adults is a relatively rare disease
that shares many histological similarities to RCC
occurring in adults and yet demonstrates some unique
clinicopathological differences. Xp11.2 translocation-
associated RCC is a common and aggressive subtype in
this age group and has heterogeneous and overlapping
morphological characteristics, causing a significant risk
of misclassification. Increased awareness and a high
index of suspicion are key to the correct recognition of
this entity.
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